The PREVENT (PREvention of Viral ENTtry) Program is an integrated preclinical-clinical research and development effort supported by the National Institutes of Health to develop novel safe and effective rectal microbicides based on plant-produced natural viral entry inhibitors.
The PREVENT clinical study will evaluate in men and women volunteers for the first time the safety, acceptability, and surrogate efficacy of a rectal microbicide containing a variant of Griffithsin (abbreviated Q-GRFT), a natural plant-derived protein with high potency against HIV-1 and other sexually transmitted viruses, including HSV-2 and HCV.
Microbicides can help minimize the risk of sexually transmitted infections (STI), including co-infection by HIV-1, HSV-2 and HCV. The goal of the PREVENT clinical trial is to evaluate for the first time the safety and tolerability of the plant-derived lectin Q-GRFT, a molecule that is far more potent than other viral entry inhibitors, yet has shown in preclinical models none of the pharmacological or safety deficiencies of other drugs in its class.
1 / 3